These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 14715540)

  • 1. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
    McSharry JJ; McDonough AC; Olson BA; Drusano GL
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
    Gubareva LV; Webster RG; Hayden FG
    Antiviral Res; 2002 Jan; 53(1):47-61. PubMed ID: 11684315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
    Boivin G; Goyette N
    Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
    Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
    Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
    Abed Y; Goyette N; Boivin G
    Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
    Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
    Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
    Govorkova EA; Fang HB; Tan M; Webster RG
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
    McKimm-Breschkin J; Trivedi T; Hampson A; Hay A; Klimov A; Tashiro M; Hayden F; Zambon M
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2264-72. PubMed ID: 12821478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
    Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
    Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
    Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
    Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.